Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.50 |
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.46 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286423 | 0.85 | PGK1 (0.58) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL27421875 | 0.82 | GABBR2 (0.54) | PGDGABRR1GABBR2GABBR1LPAR5 | |
| Monoethanolamine SCHEMBL5181889 | 0.79 | PGD (0.44) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL3950043 | 0.78 | LPAR5 (0.61) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL6655023 | 0.78 | PGK1 (0.52) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL24706048 | 0.78 | PGK1 (0.52) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL3340798 | 0.78 | PGK1 (0.52) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL3340890 | 0.78 | PGK1 (0.52) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL12282272 | 0.78 | PGK1 (0.52) | PGDPGK1PGK2MPILPAR5 | |
| SCHEMBL14278848 | 0.78 | PGK1 (0.52) | PGDPGK1PGK2MPILPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329515-B2 | Solid support for the synthesis of 3′-amino oligonucleotides | SIGMA-ALDRICH CO. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-0854938-B1 | BRANCHED PROBE AND METHOD OF DETECTING A SUBSTANCE TO BE ANALYZED | ROCHE DIAGNOSTICS GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PROLIGO LLC (US) | 2004-11-04 | — | — | US | disclosed |
| US-6503714-B1 | Contacting the sample with a probe under conditions in which said substance if present binds directly or indirectly to the probe, a plurality of nucleobases covalently attached to at least one strand of backbone comprising a plurality of atoms | ROCHE DIAGNOSTICS GMBH (DE) | 2003-01-07 | — | — | US | disclosed |
| US-6214549-B1 | CONTACTING SAMPLE WITH PROBE COMPRISING STEM AND BRANCH SUCH THAT SUBSTANCE IF PRESENT BINDS DIRECTLY OR INDIRECTLY TO PROBE; MIXING BINDING PRODUCT WITH CONJUGATE; REMOVING UNBOUND CONJUGATE FROM MIXTURE; DETERMINING PRESENCE OF CONJUGATE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-04-10 | — | — | US | disclosed |
| WO-1994004550-A1 | CHOLESTERYL-MODIFIED TRIPLE-HELIX FORMING OLIGONUCLEOTIDES AND USES THEREOF | TRIPLEX PHARMACEUTICAL CORPORATION (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PCNA, DERA, RNGTT | PGD 1546/4885PGK1 3316/4885PGK2 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.